A multicenter cohort study in France investigated the effects of glucagon-like peptide-1 (GLP-1) receptor agonists on hidradenitis suppurativa (HS) in 66 patients over a median follow-up of 19 months. Results indicated significant reductions in HS severity, symptoms, and body mass index. Notably, 54% of participants achieved at least a 1-point decrease in the Hidradenitis Suppurativa Physician’s Global Assessment score, while flare frequency decreased. Most subjects received semaglutide, and results suggest a promising role for GLP-1 RAs in managing HS, despite limitations inherent to the retrospective design.

Source: JAMA Dermatology